Sponsored By
.png?length=600&name=73739cc8-e311-4fbb-a7dd-68ee123f5d12-2-5668375logo-1.GenScriptCorporation_Logo_EN_Horizontal_FullColor-(2).png){kind=logo}
Charles River
Event Sponsor
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com. Charles River’s antibody discovery portfolio includes phage display discovery, antibody engineering, in vitro pharmacology, in vivo safety and efficacy, and custom antibody development and manufacturing. We support clients working on a wide variety of antibody targets and modalities, including multispecifics, CAR-T and ADCs. To learn more about our antibody capabilities, please visit our website here.
Study Analyses Predictive Biomarkers for COVID-19 ICU Patient Mortality
The study from the Federal University of Paraíba, Brazil analyses a series of haematological, biochemical, and inflammatory factors all contribute to the mortality of COVID-19 patients in the ICU.
Group Identify Prognostic Biomarker for SCLC and Treatment Using Chemotherapy
SCLC patients that express the gene PCDHB4 have a higher likelihood of developing a resistance to chemotherapy.
Proteomic Analysis of Serum Extracellular Vesicles Reveals Potential Biomarkers for Neuroblastoma
The proteomic analysis of extracellular vesicles is shaping up to be a promising biomarker discovery technique for diseases like neuroblastoma.
Blood Biomarkers Signal Increased Risk of Alzheimer's & MND After Multiple Rugby Concussions
Results that show rugby players that have sustained multiple concussions present with markers of neurodegenerative disease development.
Life Science Players Join €23m European Project for Precision Medicine, PRECISEU
The project will bring together life science institutions across European nations in the interest of expanding development of and access to advanced therapy medicinal products.
Feinstein Institutes Links Blood Biomarkers to Psychosis in Alzheimer's Patients
The global aging population means that rates of Alzheimer's disease are expected to reach 14 million patients by 2060, many of whom will experience psychosis.
Meet Our Expert Speakers
The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Antibody Engineering with Novel Technologies Online Symposium: 20 November 2024, GMT (UTC+0), UK
Kelly Loyet
Distinguished Scientist,
Genentech
Norbert Furtmann
Head of AI Innovation - NANOBODY® Platform,
Sanofi
Philip Kim
Professor,
University of Toronto
Tudor Arvinte
Professor of Biopharmaceutics,
University of Geneva